Invokana Lawsuit Bone Fracture Side Effect Warnings Raise Concern Over SGLT2 Inhibitor Drugs

March 14, 2016 – – TheProductLawyers.com reports on warnings released by the U.S. Food and Drug Administration (FDA) indicating that new-generation, type-2 diabetes drugs Invokana and Invokamet may decrease bone density among patients using them and also increase the overall risk of bone fracture development. Warning labels on these drugs have reflected these potential risks since the products were released to market, however, the FDA has required changes to these warnings. They have asked manufacturer Janssen Pharmaceuticals (a division of Johnson & Johnson corporation) to ensure that they indicate that bone fractures have been found to occur more commonly among patients taking Invokana than they do in patients taking placebo pills.

The FDA detailed these findings by stating, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” For many using the drug, the ease of these potential bone fractures is quite concerning, but the concerns do not stop there. In addition to increased risk of fractures, the FDA also noted an observed overall bone mineral density decrease among patients taking Invokana. This fact was tested through a study conducted on 714 elderly patients. Among those patients, those taking Invokana showed increased bone loss in both their hip and spine areas and, in addition, those taking larger doses of the drug suffered increased bone loss.

The type-2 diabetes drug’s possible link to bone loss, (as well as a similarly observed bone loss link to other SGLT2 inhibitor class drugs) have been topics of expressed concerned for more than just the FDA. The Endocrinologic and Metabolic Drugs Advisory Committee issued a public safety warning regarding bone fracture risks for patients taking these drugs which were observed during clinical trials conducted in 2013, when Invokana was first approved by the FDA and released to market. Many have commented that although the drug has been on the market such a short time, it has already been the topic of an alarming number of adverse event reports, with side effect allegations ranging from bone fractures to urinary tract infections, kidney failure, and diabetic ketoacidosis.

The attorneys of Banville Law are dedicated to keeping the public informed of these important findings and concerns. To do so more effectively, they sponsor the online resource website TheProductLawyers.com. Banville Law attorneys understand the seriousness of the conditions recently linked to Invokana and other SGLT2 class inhibitor drugs. They are working to ensure that anyone who has taken these types of drugs and who has suffered from health problems that they attribute to their use of the drugs will be provided with the opportunity to look into their legal rights. These patients may be entitled to legal action and significant compensation. To help those wishing to pursue justice in the matter, the attorneys of Banville Law are offering free legal consultations for affected parties at this time.

To request more information on Invokana lawsuits, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008645